These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32422235)

  • 1. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
    Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
    Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
    Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
    Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
    Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
    Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
    Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.
    Ravasio R; Ceccacci E; Nicosia L; Hosseini A; Rossi PL; Barozzi I; Fornasari L; Zuffo RD; Valente S; Fioravanti R; Mercurio C; Varasi M; Mattevi A; Mai A; Pavesi G; Bonaldi T; Minucci S
    Sci Adv; 2020 Apr; 6(15):eaax2746. PubMed ID: 32284990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
    Maes T; Mascaró C; Tirapu I; Estiarte A; Ciceri F; Lunardi S; Guibourt N; Perdones A; Lufino MMP; Somervaille TCP; Wiseman DH; Duy C; Melnick A; Willekens C; Ortega A; Martinell M; Valls N; Kurz G; Fyfe M; Castro-Palomino JC; Buesa C
    Cancer Cell; 2018 Mar; 33(3):495-511.e12. PubMed ID: 29502954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block.
    Maiques-Diaz A; Nicosia L; Basma NJ; Romero-Camarero I; Camera F; Spencer GJ; Amaral FMR; Simeoni F; Wingelhofer B; Williamson AJK; Pierce A; Whetton AD; Somervaille TCP
    Oncogene; 2022 Oct; 41(44):4841-4854. PubMed ID: 36171271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia.
    Tatsumi G; Kawahara M; Yamamoto R; Hishizawa M; Kito K; Suzuki T; Takaori-Kondo A; Andoh A
    Leukemia; 2020 Mar; 34(3):746-758. PubMed ID: 31676828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
    Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
    Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.
    Liu L; Liu L; Leung LH; Cooney AJ; Chen C; Rosengart TK; Ma Y; Yang J
    J Biol Chem; 2015 Apr; 290(17):10599-609. PubMed ID: 25737450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia.
    van Bergen MGJM; van der Reijden BA
    Front Oncol; 2019; 9():1027. PubMed ID: 31649884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML.
    Nicosia L; Boffo FL; Ceccacci E; Conforti F; Pallavicini I; Bedin F; Ravasio R; Massignani E; Somervaille TCP; Minucci S; Bonaldi T
    Oncogene; 2022 Feb; 41(6):878-894. PubMed ID: 34862459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-
    Smitheman KN; Severson TM; Rajapurkar SR; McCabe MT; Karpinich N; Foley J; Pappalardi MB; Hughes A; Halsey W; Thomas E; Traini C; Federowicz KE; Laraio J; Mobegi F; Ferron-Brady G; Prinjha RK; Carpenter CL; Kruger RG; Wessels L; Mohammad HP
    Haematologica; 2019 Jun; 104(6):1156-1167. PubMed ID: 30514804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
    Fang Y; Liao G; Yu B
    J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma.
    Lee C; Rudneva VA; Erkek S; Zapatka M; Chau LQ; Tacheva-Grigorova SK; Garancher A; Rusert JM; Aksoy O; Lea R; Mohammad HP; Wang J; Weiss WA; Grimes HL; Pfister SM; Northcott PA; Wechsler-Reya RJ
    Nat Commun; 2019 Jan; 10(1):332. PubMed ID: 30659187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.